Akari Therapeutics Plc - ADR
AKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.81M
Close$
$5.29
64.7% downside
Current Fair Value
64.7% downsideOvervalued by 64.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $18.81 Million |
|---|---|
| Enterprise Value | $16.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-20800 |
| Beta | 0.65 |
| Outstanding Shares | 21,040 |
Return
| Return on Equity | -195.32% |
|---|---|
| Return on Assets | -82.88% |
| Return on Invested Capital | -141.60% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-1.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-1.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.20%▼ 13.03% |
|---|---|
| Total Invested | $307,250▼ 76.12% |
| Investors Holding | 6▼ 15.00% |
ESG Score
No data
About Akari Therapeutics Plc
CEO: David Solomon